65 results about "D-glucitol" patented technology

The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

A cocrystal of (1S)-1,5-anhydro-1-[3-(1-benzothien-2-ylmethyl)-4-fluorophenyl]-D-glucitol and L-proline. It is a cocrystal of known compound A, which has a constant quality, is superior in storage stability, has no moisture absorptivity, and is suitable as a crystal of a drug substance used for preparing pharmaceuticals.

Disclosed herein are pet food compositions. In one embodiment, pet food compositions which are described comprise a component selected from 2-deoxy-D-glucose; 5-thio-D-glucose; 3-O-methylglucose; 1,5-anhydro-D-glucitol; 2,5-anhydro-D-mannitol; mannoheptulose; and mixtures thereof. In yet another embodiment, pet food compositions which are described comprise an extract of plant matter selected from avocado, alfalfa, fig, primrose, and mixtures thereof. The pet food compositions may be prepared by any of a variety of processes including, but not limited to, optional processes described herein.

This invention relates to a novel pharmaceutical composition which may be administered parenterally to a mammal for the production of general anaesthesia, specifically to a limpid, stable, injectable pharmaceutical formulation of 2,6-diisopropylphenol. The formulation comprises 2,6-diisopropylphenol, a compound of the following general formula (I) wherein R1 and R2 can be the same or different and are hydrogen or lower alkyl group containing 1-3 carbons or acetate group and optionally water and / or one or more antioxidants.

The invention discloses a polyurethane composition for glass fiber reinforced honeycomb sandwich panels and an application method of the polyurethane composition. The polyurethane composition comprises a component A and a component B; the component A comprises 40-70% of polyether polyol 1, 5-10% of polyether polyol 2, 5-10% of polyether polyol 3, 0-10% of polyester polyol 1, 4-10% of crosslinkingagents, 5-15% of chain extenders, 0.2-2% of foam stabilizers, 0.2-1.5% of catalysts, 5-10% of flame retardants, 0.2-1% of water, 0.2-2% of internal releasing agents and 0.2-1% of other additive; the component B comprises polyaryl polymethylene isocyanate; the polyether polyol 1 is prepared by taking D-glucitol as an initiator and alkali metal hydroxide as a catalyst, performing anionic polymerization on 1,2-propylene oxide and adding ethylene oxide for terminating; the polyether polyol 2 is propylene oxide polyether polyol with the functionality being 2, and is prepared by taking bisphenol A as an initiator; the polyether polyol 3 is prepared by taking glycerol as an initiator and is terminated by ethylene oxide; the polyester polyol 1 is obtained by polycondensation reaction between terephthalic acid and ethylene glycol.

Disclosed herein are pet food compositions. In one embodiment, pet food compositions which are described comprise a component selected from 2-deoxy-D-glucose; 5-thio-D-glucose; 3-O-methylglucose; 1,5-anhydro-D-glucitol; 2,5-anhydro-D-mannitol; mannoheptulose; and mixtures thereof. In yet another embodiment, pet food compositions which are described comprise an extract of plant matter selected from avocado, alfalfa, fig, primrose, and mixtures thereof. The pet food compositions may be prepared by any of a variety of processes including, but not limited to, optional processes described herein.

An anti-viral compounds effective against viruses belonging to the Flaviviridae family, wherein the anti-viral compounds are 1,5-dideoxy-1,5-imino-D-glucitol derivative compounds having the general formula (I)wherein R2, R3, R4 and R5 are the same or different and are selected from the group consisting of hydrogen, acyl, benzyl, alkyl, aryl, sulfonyl, phosphonyl, silyl, R6 is at least one of alkyl or branched alkyl, heteroalkyl or aryl, R6′ is a bridging group selected from at least one of bicycle[2.2.1]heptyl, bicycle[3.2.1]octyl, oxa analogs, admonyl and cubyl, n′=2-10, n″=1-10, enantiomers and stereoisomers of said compounds and physiologically acceptable salts or solvates of said compounds, enantiomer or stereoisomer.

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating / immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating / immuno-stimulating agents.

A choline salt crystal of (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol which shows an endothermic peak at 194 to 198° C. as measured by differential scanning calorimetry (DSC analysis) and shows main peaks at about 2θ (°) 5.58, 14.72, 16.80, 17.82, 21.02, and 22.46 as measured by X-ray powder diffraction. Thus, a crystal of an azulene compound can be produced which is in a single crystal form, has a constant quality, can be produced with good reproducibility, can be provided stably as a crystal of an drug substance for use in the preparation of a pharmaceutical and is excellent in storage stability.

The present invention provides a pharmaceutical composition useful as a therapeutic agent for fatty liver disease. A pharmaceutical composition, which comprises (1S)-1,5-anhydro-1-[5-(azulen-2-ylmethyl)-2-hydroxyphenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, (1S)-1,5-anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, or alternatively, (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol or a pharmaceutically acceptable salt thereof, more specifically such a pharmaceutical composition for treating fatty liver disease, such as nonalcoholic fatty liver disease in one embodiment, or nonalcoholic simple fatty liver and / or nonalcoholic steatohepatitis in another embodiment.

The present invention provides a peritoneal dialysis solution that contains heat stable osmotic agents such as D-glucitols, gluconic acids and alkylglycosides produced the reduction, oxidation or glycosylation of icodextrins respectively. As a result, osmotic agents that are stable under autoclaving or heat sterilization conditions are provided which reduces the amount of bioincompatible materials in the sterilized peritoneal dialysis solutions. Methods of preparing the D-glucitols, gluconic acids and alkylglycosides are disclosed.

The invention discloses a high-concentration glucose removal method for determining serum 1,5 anhydro-D-glucitol based on a pyranose oxidase method, which comprises the following steps: preparing a 2-morpholinoethanesulfonic acid (MES) buffer solution having a pH value of 6.0-9.0, wherein the MES buffer solution contains a certain amount of glucokinase (GK), glucose-6-phosphate dehydrogenase (G6PD), nicotinamide adenine dinucleotide phosphate (NADP), pyruvate kinase (PK), phosphoenolpyruvate (PEP) and adenosine triphosphate (ATP); and adding into a serum sample containing glucose (Glu), and reacting at 20-50 DEG C for 3-5 minutes, wherein the GK converts the Glu into glucose-6-phosphoric acid (G6P) in the presence of the ATP, and adenosine diphosphate (ADP) is generated at the same time; the G6P is further converted into glucose-6-phosphate lactone (G6PL) by the G6PD in the presence of the NADP+; and the ADP generated in the reaction is converted into ATP again under the action of thePK in the presence of the PEP. The glucose removal agent prepared by the method can be stably stored at 2-8 DEG C for 14 months, and can be used for a clinical biochemical autoanalyzer extensively used at present.

The invention discloses a pancreatic cancer diagnostic marker combination as well as application and a determination method thereof. The pancreatic cancer diagnostic marker combination comprises 15 differentiated metabolites (2,5-dihydroxybenzoic acid, talopyranose, proline, glutamate, choline, 1,5-anhydro-D-glucitol, tryptophan, glutamine, betaine, 2-oxoglutaric acid, methylguanidine, adenine, glycocholic acid, valine and 2-aminobutyric acid). The invention further provides a combination of the 15 differentiated metabolites to serve as a marker for early discovery and diagnosis of pancreatic cancer, application and a diagnostic marker determination method, and the method is a liquid-phase / gas-phase chromatography-mass spectrometry combined metabonomics analysis method based on plasma / serum of patients with pancreatic cancer. The pancreatic cancer diagnostic marker combination provided by the technical scheme of the invention has the characteristics of being high in sensitiveness and specificity, has relatively high sensitiveness and specificity on early pancreatic cancer diagnosis, can be used for early discovery of pancreatic cancer, gains time for the patients to receive treatment as soon as possible, and improves the clinical treatment effect.

The invention relates to a method for synthesizing irregular glucitol (1S)-1,5-dehydration-1-[4-chlorine-3-[(4-ethyoxyl phenyl) methyl] phenyl]-D-glucitol. The reaction formula of the compound is as shown in the specification. The method is gentle in process reaction condition, simple and convenient to operate, applicable to industrial production and relatively high in total product yield, that is, the total product yield is 43-53%, and medicine-grade irregular glucitol 6 is easily prepared.

The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases.A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.

N-Substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds of Formula I are effective in treatment of hepatitis infections, including hepatitis B and hepatitis C. In treating hepatitis infections, the compounds of Formula I may be used alone, or in combination with another antiviral agents selected from among nucleosides, nucleotides, immunomodulators, immunostimulants or various combinations of such other agents.

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating / immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating / immunostimulating agents.

A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like:or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

The present invention provides a 1-thio-D-glucitol compound of the following formula, which shows the action of inhibiting the activity of SGLT2, a pharmaceutically acceptable salt of the compound, or a hydrate of the compound or the salt; and a pharmaceutical comprising such a compound as an active ingredient, especially, a pharmaceutical for preventing or treating diabetes, diabetes-related disease, or diabetic complication. The invention also provides a method for producing the 1-thio-D-glucitol compound and its intermediate.

The invention discloses an reagent for enzymatic determination of 1,5-anhydro-D-glucitol. At present, determination operation has a lot of trouble and is difficult to be detected in bulk, and in the methods for the operation, the reagent only can be prepared when being used without long term preservation. The reagent of the invention comprises the following components with the contents in 1 liter of water: 60-140 mmol of 3-hydroxyl methyl amino methane, 2.26-2.38 mmol of oxidized coenzyme II (NADP+), 1-5 grams of trehalose, 0.1-0.6 activity unit of 2-methyl-4-isothiazole-3-ketone, 0.1-0.6 gram of Twain, 1000-3000U of ADP-dependent hexokinase (ADP-HK), 1000-80000U of AG-6-phosphate dehydrogenase and 0.1-0.3 mmol of adenosine diphosphate (ADP). The invention is used for determining 1,5- anhydro-D-glucitol.

Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating / immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating / immuno-stimulating agents.

The present invention relates to methods and compositions of treating or preventing inflammatory diseases or conditions in a patient comprising administering to the patient a therapeutically effective amount of a composition comprising a glutathione donor, 5-amino 4-i mid azolecarboxamide ribotide (AICAR), a 3-hydroxy-3-methylgluatryl-coenzymeA (HMG-CoA) reductase inhibitor, D-threo-1-Phenyl-2-decanoylamino-3-morpholino-1-propanol HCl (D-PDMP), and / or 1,5-(butylimino)-1,5-dideoxy-D-glucitol (Miglustat), or derivatives thereof.

The invention discloses a rose beautifying beef jerk and a preparation method thereof. The rose beautifying beef jerk is prepared from the following raw materials in parts by weight: 1-2 parts of green onion juice, 1-2 parts of rose powder, 2-3 parts of periwinkie meat, 4-5 parts of grape seed oil, 0.5-1 parts of platycodon grandiflorum, 0.5-1 parts of buckwheat, 0.5-1 parts of cushaw flowers, 100-110 parts of beef, 0.4-0.5 parts of papain, 1.8-2.0 parts of calcium chloride, 1.8-2.0 parts of D-Glucitol, 5-6 parts of edible salt, 0.03-0.04 parts of Lactobacillus casei, 0.1-0.2 parts of SodiuM different VC, 12-15 parts of Ginger slice, 10-12 parts of ginger juice, 2-3 parts of aginomoto, 5-6 parts of white granulated sugar, 1-2 parts of soy sauce, 6-8 parts of yellow rice or millet wine, 3-4 parts of pepper, 1-2 parts of cinnamon, 1-2 parts of anise, 1-2 parts of fennel, 18-20 parts of 140mg / ml tangerine peel extracting liquid, and a proper amount of water. The production technology is good, the mouthfeeling is refreshing and smooth, rose can beautify the skin, and the added traditional Chinese medicines have efficacies of relieving cough and eliminating phlegm.